江南官方全站app下载(中国)官方网站-iOS/Android通用版

Press Releases
Home News

Press Releases

Available Now! Hansoh Pharma's Hengmu (Tenofovir Amibufenamide Tablets) - A Breakthrough Class 1 Hepatitis B Drug Launches Nationwide Supply
Release Date:2021/06/26
Font Size

On June 26, Hansoh Pharma's new Class 1 drug Hengmu (Tenofovir Amibufenamide Tablets) started nationwide supply. Hengmu is a new second-generation tenofovir independently developed by Hansoh Pharma, and also the first oral anti-hepatitis B virus (HBV) drug originally developed in China, for the treatment of adult patients with chronic hepatitis B. Compared with tenofovir disoproxil fumarate (TDF), Hengmu requires less than one-tenth the dose to achieve similar antiviral efficacy, and delivers comparable antiviral efficacy as first-line drugs and better bone and kidney safety. The launch of Hengmu will provide a new option for the treatment of hepatitis B in China. 


▲ Hengmu (Tenofovir Amibufenamide Tablets) 


▲ Good news for hepatitis B patients; Hengmu started nationwide supply 


Hengmu on the production line

 

▲ Strengthen lean management and provide whole-process drug quality and safety control to meet the medication requirements of hepatitis B patients with high quality


Hengmu ready to go 

▲ Race against time to accelerate accessibility and ensure supply; loading of Hengmu is under way in an intense and orderly manner.


First shipment of Hengmu 


▲ In response to patients' expectations for a better tomorrow, boxes of Hengmu are shipped to all parts of the country at full speed to protect patients' health with technological innovation.